Finn
BMRN Biotechnology · Rare disease · High leverage · Competition · Thesis updated November 8, 2026

BioMarin expands portfolio but faces debt and new competitive pressure

01 Running thesis

Diversification with growing pressures

BioMarin is testing a new strategy. The April 2026 Amicus acquisition added Galafold for Fabry disease and Pombiliti plus Opfolda for late-onset Pompe disease. This gives BioMarin more products and less reliance on Voxzogo alone. Management laid out clear targets, aiming for $1.4 billion in peak sales for Galafold and $220 million in annual cost synergies by 2028.

The bull case points to a more profitable rare disease leader. If BioMarin grows Voxzogo, hits its peak sales targets for the acquired drugs, and achieves the $220 million in synergies, the combined cash flow will allow the company to rapidly pay down debt. Early updates show that Amicus cost synergies are tracking ahead of schedule.

The bear case centers on execution risk, debt, and new competition. Total debt sits at roughly $4.3 billion. Voxzogo is facing new pressure in the US market, with a switch rate to a competitor reaching 15 percent. Management announced they will stop reporting this switch metric going forward, raising transparency concerns. Furthermore, a recent $70 million order deferral highlights the vulnerability of the international revenue base.

The upcoming year requires proof of execution. Investors are watching to see if the Voxzogo switch rate stabilizes, whether the $70 million deferred order is realized in early 2027, and how the pending ITC patent case resolves in December 2026.

Nov 2026▼BioMarin noted a $70 million international order deferral and a 15 percent US competitive switch rate for Voxzogo. The company also added new pipeline assets and set a May 2027 FDA target date for Voxzogo in hypochondroplasia.
Aug 2026▼BioMarin discontinued BMN 401 after a trial failure and noted a 10 percent US competitive switch rate for Voxzogo. Management also established peak sales targets for the Amicus assets.
May 2026→The Amicus acquisition closed in April 2026, adding two commercial products and lifting total debt to about $4.3 billion. The thesis improves on diversification, but the debt and integration risk offset much of that benefit.
Feb 2026▼BioMarin finalized its exit from Roctavian and recorded about $240.0 million of restructuring charges. It also set up the Amicus deal, which increased the future debt risk.
Oct 2025→BioMarin moved to divest Roctavian after weak sales. That reduced one source of uncertainty, but left more pressure on Voxzogo and new pipeline assets.
Aug 2025▲Voxzogo continued to grow, with second quarter 2025 revenue of $221.4 million. Cost control helped the story, while the Inozyme acquisition added a new late-stage pipeline risk.
May 2025▲The first quarter of 2025 showed strong Voxzogo growth and lower research and development expense. Enrollment was also completed for the pivotal Voxzogo hypochondroplasia study.
02 Business model

Rare diseases, high prices, small markets

BioMarin focuses entirely on rare genetic diseases. Because these patient groups are very small, the company relies on high per-patient pricing to recover development costs. This requires broad access agreements with insurers and government buyers.

Historically, the model worked well once a drug became the standard of care. Voxzogo, Vimizim, and Naglazyme built a strong base, generating a combined $560.2 million in the first quarter of 2026. The Amicus acquisition broadens this base significantly, bringing established enzyme therapies for Fabry and Pompe diseases.

However, this broader model comes with increased complexity. BioMarin must now manage a much larger debt load, integrate new sales teams, and handle more complex manufacturing. High reliance on large international orders also introduces quarter-to-quarter revenue lumpiness, as seen with recent order delays in the Middle East.

03 Product portfolio

The drugs that drive the story

Growth engine

Voxzogo

Voxzogo treats achondroplasia and is a major growth driver. It faces a 15 percent competitive switch rate in the US and awaits a key FDA decision for hypochondroplasia in May 2027.

Cash cow

Galafold

Acquired from Amicus in April 2026, Galafold treats Fabry disease. Management believes it can reach $1.4 billion in peak sales.

Steady

Pombiliti and Opfolda

Also acquired from Amicus, this combination treats late-onset Pompe disease. BioMarin targets $1.2 billion in peak sales.

Cash cow

Vimizim

Vimizim treats MPS IVA and produced $210.2 million of net product revenue in early 2026. It provides steady cash flow.

Steady

Naglazyme

Naglazyme treats MPS VI and generated $130.1 million in early 2026. Manufacturing complexities have caused recent margin pressure.

Option

BMN 820

BioMarin acquired US rights to BMN 820 for focal segmental glomerulosclerosis in April 2026. It is an early stage pipeline bet.

04 Business segments

Q1 mix before Amicus

Voxzogo29%modest
Vimizim27%modest
Naglazyme17%modest
Palynziq12%declining
Other products15%flat

This mix uses first quarter 2026 net product revenue from the March 31, 2026 10-Q. It does not include Galafold or Pombiliti and Opfolda, because the Amicus deal closed after the quarter ended.

05 Risk factors

What could go wrong

Voxzogo loses market share

High impact · High odds

The high price model is vulnerable to competition. Management noted that approximately 15 percent of US Voxzogo patients switched to a competitor, and the company will no longer report this metric.

We watchWatch Voxzogo revenue growth and pricing updates.

Amicus integration misses targets

High impact · Medium odds

BioMarin spent about $4.8 billion on Amicus. If it fails to reach its peak sales targets or cannot achieve the $220 million in cost synergies, the deal will destroy value.

We watchWatch quarterly sales for Galafold and Pombiliti, synergy updates, and integration costs.

International order lumpiness

Medium impact · Medium odds

High reliance on large international orders introduces quarter-to-quarter revenue lumpiness. A recent $70 million order deferral highlighted this vulnerability.

We watchWatch for the resolution of the $70 million deferred order in early 2027.

Debt limits flexibility

High impact · Medium odds

Total debt rose to roughly $4.3 billion after the Amicus close. The resulting interest expense could strain finances if the new commercial assets underperform.

We watchWatch total debt levels, interest expense, and free cash flow generation.

Adverse patent rulings

High impact · Medium odds

An ongoing ITC patent case creates near-term binary risk for the company's intellectual property. A final decision is expected in December 2026.

We watchWatch for the final ITC decision expected on December 21, 2026.
06 Quick answers

In one breath

What does BioMarin do?

BioMarin develops and sells medicines for rare genetic diseases. Its main products include Voxzogo, Vimizim, Naglazyme, and the newly acquired Amicus products.

Why did BioMarin buy Amicus?

The acquisition added Galafold for Fabry disease and Pombiliti plus Opfolda for late-onset Pompe disease. It diversifies revenue but added significant debt.

Is Voxzogo facing competition?

Yes. Management recently stated that about 15 percent of US patients switched to a competitor. The company will stop reporting this specific metric going forward.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 8, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. BioMarin Q3 2026 Earnings Transcript
  2. BioMarin Q2 2026 Form 10-Q
  3. BioMarin Q1 2026 Form 10-Q
08 Explore the industry

Comparable Biotechnology companies

Companies near BioMarin Pharmaceutical Inc. in Finn's Biotechnology industry ranking.

Get started with Finn today